SavedAdd your journal

Journals / Mikrobiyoloji Bülteni / 2008 / Cilt: 42 - Sayı: 4

Investigation of pyrazinamide resistance in multidrug-resistant tuberculosis cases in Hospital of Pulmonary Diseases, Izmir, Turkey

İzmir Göğüs Hastalıkları Hastanesinde çok ilaca dirençli tüberküloz olgularında pirazinamid direncinin araştırılması

Güneş ŞENOL
Meral COŞKUN
Ayriz Tuba GÜNDÜZ
Can BİÇMEN
Mine GAYAF
Ayşe ÖZSÖZ
Pages
591–597
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In conclusion, due to the high PZA resistance rate in MDR-MTB isolates, susceptibility testing against PZA should be done in MDR-TB cases; however, since PZA resistance rate was low in new susceptible cases, it was thought that testing susceptibility of PZA is not necessary as a routine procedure in our region.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Pyrazinamide (PZA) is one of primary drugs for antituberculous treatment.
📊
Key Findings & Data:The aim of this study was to determine the rates of PZA resistance in multidrug-resistant (MDR) and susceptible Mycobacterium tuberculosis (MTB) strains isolated from patients who were admitted to our hospital.
💡
Conclusion & Impact:In conclusion, due to the high PZA resistance rate in MDR-MTB isolates, susceptibility testing against PZA should be done in MDR-TB cases; however, since PZA resistance rate was low in new susceptible cases, it was thought that testing susceptibility of PZA is not necessary as a routine procedure in our region.
🔬Design:Research Article
📍Scope:2005-2007 Verileri
⚙️Variables:Antitüberküler ajanlar · Mikrobiyal duyarlılık testleri · Mycobacterium tuberculosis

Abstract

Pyrazinamide (PZA) is one of primary drugs for antituberculous treatment. The aim of this study was to determine the rates of PZA resistance in multidrug-resistant (MDR) and susceptible Mycobacterium tuberculosis (MTB) strains isolated from patients who were admitted to our hospital. MDR strains have been isolated between 2005-2007 years, and susceptible strains were chosen randomly among the collection of the strains of the same period. MTB isolates were grown in BACTEC 960 full automatized broth system (Becton Dickinson, Sparks, MD) and Lowenstein-Jensen solid medium. Identification was done by radiometric BACTEC 460 NAP procedure. Antibiotic susceptibility testing against conventional anti-tuberculous drugs (streptomycin, isoniazide, rifampisin, etambutol) was performed by the radiometric BACTEC 460 system and PZA susceptibility was worked out by BD MGIT 960 PZA Kit (Becton Dickinson, Sparks, MD) with the use of 100.0 microg/ml critical concentrations of PZA. As a result, two of the 65 (3.1%) MTB susceptible strains and 16 of 63 (25.4%) MDR-MTB isolates were found resistant to PZA. In conclusion, due to the high PZA resistance rate in MDR-MTB isolates, susceptibility testing against PZA should be done in MDR-TB cases; however, since PZA resistance rate was low in new susceptible cases, it was thought that testing susceptibility of PZA is not necessary as a routine procedure in our region.

Özet

Pirazinamid (PZA), tüberküloz (TB) tedavisinde kullanılan birincil ilaçlardandır. Bu çalışmada, hastanemize başvuran olgulardan izole edilen çok ilaca dirençli (ÇİD) TB ve tüm birincil anti-TB ilaçlara (streptomisin, izoniazid, rifampisin, etambutol) duyarlı Mycobacterium tuberculosis (MTB) izolatlarında PZA direnç oranlarının belirlenmesi amaçlanmıştır. Çalışma, 2005-2007 yılları arasında hastanemiz laboratuva-rında izole edilmiş ÇİD-MTB izolatlarını ve yine aynı dönem içinde izole edilen duyarlı suşlardan rastğele seçilmiş MTB izolatlarını kapsamaktadır. MTB izolatlarının kültürü, BACTEC 960 sıvı bazlı otomatize kültür sisteminde (Becton Dickinson, Sparks, MD) ve Lövvenstein-jensen katı besiyerinde yapılmıştır. Tiplen-dirmede BACTEC NAP prosedürü kullanılmıştır. Konvansiyonel birinci sıra anti-TB ilaç duyarlılığı, radyo-metrik BACTEC 460 sistemi, izolatların PZA duyarlılığı ise 100.0 pg/ml PZA kritik konsantrasyonu kullanılarak BD M GİT 960 PZA Kit (Becton Dickinson, Sparks, MD) ile çalışılmıştır. Çalışmaya alınan .65 adet birincil anti-TB ilaçlara duyarlı MTB izolatının 2 (%3.1)'sinde ve 63 adet ÇİD-MTB izolatının 16 (%25.4)'sın-da PZA direnci saptanmıştır. Sonuç olarak, bölgemizde ÇİD-MTB izolatlarında saptanan yüksek PZA direnç oranı nedeniyle ÇİD-TB olgularında PZA duyarlılığının çalışılması gerektiği, ancak yeni olgularda direncin düşük oranda bulunması nedeniyle rutin PZA duyarlılık testinin uygulanmasına gerek olmadığı düşünülmüştür.

🔖

Cite This Article

ŞENOL, G., COŞKUN, M., GÜNDÜZ, A. T., BİÇMEN, C., GAYAF, M., ÖZSÖZ, A. (2008). Investigation of pyrazinamide resistance in multidrug-resistant tuberculosis cases in Hospital of Pulmonary Diseases, Izmir, Turkey. Mikrobiyoloji Bülteni, Cilt: 42 - Sayı: 4, 591–597. https://ajindex.com/articles/299372

References (6)

  1. World Health Organization. Global tuberculosis control: surveillance, planning, financing. WHO report 2007.
  2. World Health Organization, Geneva. WHO/HTMATB/2007, 376. 2.Centers for Disease Control and Prevention. Initial therapy for tuberculosis in the era of multidrug resistance. Recommendations of the advisory council for the elimination of tuberculosis. MMWR 1993; 42 (RR-7): 1 -8. 3.Centers for Disease Control and Prevention. Controlling Tuberculosis in the United States. Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America. MMWR 2005; 54 (RR-12): 1-81. 4.National Committee for Clinical Laboratory Standards. Susceptibility Testing of Mycobacteria, Nocardia, and other aerobic Actinomycetes. Approved Standard, NCCLS Document M24-A, 2003.
  3. Wayne, Pennsylvania. 5.Kiraz N. Antitüberküloz ilaçlara direnç mekanizmaları ve yeni ilaçlar, s: 174-7. 21. Yüzyılda Tüberküloz Sempozyumu ve II. Tüberküloz Laboratuvar Tanı Yöntemleri Kursu Kurs Kitabı, 11-12 Haziran 2003, Samsun. 6.Çilli A. Antitüberküloz ilaçlar ve etki mekanizmaları, s: 163-9. 21. Yüzyılda Tüberküloz Sempozyumu ve II. Tüberküloz Laboratuvar Tanı Yöntemleri Kursu Kurs Kitabı, 11-12 Haziran 2003, Samsun. 7.Pfyffer GE, Palicova F, Rüsch-Gerdes S. Testing of susceptibility of Mycobacterium tuberculosis to pyrazinami-de with the nonradiometric BACTEC MGIT 960 system. ] Clin Microbiol 2002; 40: 1670-4. 8.Della-Latta P. Mycobacteriology and Antimycobacterial Susceptibility Testing, pp: 7.7.1 - 7.8.5. In: Isenberg HD (ed-in-chief), Clinical Microbiology Procedures Handbook. 2004, 2nd ed. ASM Press,
  4. Washington, DC. 9.Woods GL. Susceptibility testing for mycobacteria. Clin Infect Dis 2000; 31: 209-11. 10.Siddiqi SH. BACTEC 460TB System Product and Procedure Manual. 1996,
  5. Becton Dickinson and Company, Maryland, USA. 11.The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance: Anti-tuberculosis drug resistance in the world. Report number 3. 2004, Geneva. 12.World Health Organization. Guidelines for the management of drug-resistant tuberculosis. 1997,
  6. Geneva, Switzerland. 13.Cheng SJ, Thibert L, Sanchez T, Heifets L, Zhang Y. pncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: spread of a monoresistant strain in Quebec, Canada. Antimicrob Agents Chemother 2000; 44: 528-32. 14.Durmaz R. Mycobacterium tuberculosis' de direnç sorunu. Ankem Derg 2005; 19: 107-10. 15.Yolsal N, Malat G, Dişçi R, Örkün M, K